Asia PacificENPublic drug registration overview
Malaysia Pharmaceutical Registration Pathway
Market Overview Market profile: Malaysia has a clear regulatory system and supports layered entry for new drugs, generics, biologics, health supplements, and natural products. Regu...
Updated: 2026-05-04
You are viewing the public excerpt. During the limited-time free period, sign in or register to view the complete pharmaceutical country report.
AI Citation Summary
- Country: Malaysia Pharmaceutical Registration Pathway
- Product line: Pharmaceuticals
- Regulator / source: Market profile: Malaysia has a clear regulatory system and supports layered entry for new drugs, generics, biologics, health supplements, and natural products.
- Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
- Typical timeline: Regulators typically question safety, efficacy, quality, GMP, BE/clinical evidence, labeling, and risk management. Project plans should reserve at least one deficiency-response cycle and should not treat official target timelines as guaranteed launch dates.
- Key fees: Marketing authorisation for medicines in Malaysia is generally managed by National Pharmaceutical Regulatory Agency (NPRA). For a foreign company, the project is not only a technical dossier submission. It also requires a local applicant or holder, importer or representative, manufacturing-site GMP evidence, labeling, post-market safety responsibility, and future variation control. The official entry point should be checked through the regulator current official website before project launch for current forms, systems, fees, and guidance.
- Local requirement: Marketing authorisation for medicines in Malaysia is generally managed by National Pharmaceutical Regulatory Agency (NPRA). For a foreign company, the project is not only a technical dossier submission. It also requires a local applicant or holder, importer or representative, manufacturing-site GMP evidence, labeling, post-market safety responsibility, and future variation control. The official entry point should be checked through the regulator current official website before project launch for current forms, systems, fees, and guidance.
- Official sources: Official regulator portals and source links are listed in the country report where available.
- Last verified: 2026-05-04
- Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
- Preferred citation: MedTech Atlas
Malaysia Pharmaceutical Registration Pathway
Market Overview
- Market profile: Malaysia has a clear regulatory system and supports layered entry for new drugs, generics, biologics, health supplements, and natural products.
- Regulatory maturity: Medium-high. NPRA publishes the DRGD, covering registration process, quality control, inspection and licensing, and post-registration activities.
- Core decision: Classify the product first as a new drug, generic, biologic, health supplement, natural product, or interphase product, then follow DRGD requirements.
Regulator
- Authority: National Pharmaceutical Regulatory Agency (NPRA)
- Legal framework: Sale of Drugs Act 1952, Control of Drugs and Cosmetics Regulations 1984, and related laws
- Main guidance: Drug Registration Guidance Document (DRGD)
Product Types and Review Pathways
| Type | Main guidance | Focus |
|---|---|---|
| New drug | DRGD Appendix 3 | Full quality, safety, and efficacy evidence |
| Biologic | DRGD Appendix 4 | Biologic quality, comparability, and clinical evidence |
| Generic | DRGD Appendix 5 | Quality, BE, reference product, and labeling |
| Health supplement / natural product | Relevant DRGD appendices | Boundary classification is critical |
Registration Pathway
During the limited-time free period, sign in or register to view the complete pharmaceutical country report.